Croatia's Podravka holds first-half profit at €41.1mn as pharma unit leads growth
Croatia's Podravka held normalised net profit at €41.1mn in the first half of 2026 as operating revenue rose to €520.7mn, with pharmaceutical unit Belupo posting the strongest growth at 7.1%.
Read the full story at bne IntelliNews →